Амбулаторное лечение тромбоза глубоких вен ривароксабаном: опыт работы в одном центре

Авторы:
  • К. В. Лобастов
    ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России, Москва, Россия
  • А. В. Воронцова
    ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России, Москва, Россия
  • А. Б. Барганджия
    ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России, Москва, Россия
  • И. В. Счастливцев
    ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России, Москва, Россия
  • Л. А. Лаберко
    ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России, Москва, Россия
Журнал: Флебология. 2020;14(2): 99-106
Просмотрено: 131 Скачано: 184

Список литературы:

  1. Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A. Weitz JI. ISTH Steering Committee for World Thrombosis Day, Thrombosis: a major contributor to global disease burden. Arteriosclerosis, Thrombosis, and Vascular Biology. 2014;34(11):2363-2371. https://doi.org/10.1161/ATVBAHA.114.304488
  2. The general prevalences of diseases in the total population of Russia in 2012. Statistical Materials, Part II 2013. (In Russ.) 2013 [cited 2020 11.02]. Available from: http://www.rosminzdrav.ru/documents/8029-statisticheskaya-informatsiya-2012
  3. The prevalences of diseases in the total population of Russia in 2014. Statistical Materials, Part II 2015. (In Russ.) 2015 [cited 2020 11.02]. Available from: https://www.rosminzdrav.ru/documents/9479-statisticheskaya-informatsiya-za-2014
  4. The prevalences of diseases in the total population of Russia in 2016. Statistical Materials, Part II 2017. (In Russ.) 2017 [cited 2020 11.02]. Available from: https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2016-god
  5. Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy. 2009;29(8):943-953. https://doi.org/10.1592/phco.29.8.943
  6. Jha AK, Larizgoitia I, Audera-Lopez C, Prasopa-Plaizier N, Waters H, Bates DW. The global burden of unsafe medical care: analytic modelling of observational studies. BMJ Quality & Safety. 2013;22(10):809-815. https://doi.org/10.1136/bmjqs-2012-001748
  7. Egermayer P. The effects of heparin and oral anticoagulants on thrombus propagation and prevention of the postphlebitic syndrome: a critical review of the literature. Progress in Cardiovascular Diseases. 2001;44(1):69-80. https://doi.org/10.1053/pcad.2001.24684
  8. Aissaoui N, Martins E, Mouly S, Weber S, Meune C. A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both. International Journal of Cardiology. 2009; 137(1):37-41. https://doi.org/10.1016/j.ijcard.2008.06.020
  9. Othieno R, Okpo E, Forster R. Home versus in-patient treatment for deep vein thrombosis. The Cochrane Database of Systematic Reviews. 2018;1(1): CD003076. https://doi.org/10.1002/14651858.CD003076.pub3
  10. Roussin A. Effective management of acute deep vein thrombosis: direct oral anticoagulants. Int Angiol. 2015;34(1):16-29.
  11. Merli GJ, Hollander JE, Lefebvre P, Laliberté F, Raut MK, Olson WH, Pollack CV Jr. Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban. Hospital Practice (1995). 2015;43(2):85-93. https://doi.org/10.1080/21548331.2015.1021659
  12. Margolis JM, Deitelzweig S, Kline J, Tran O, Smith DM, Bookhart B, Crivera C, Schein J. Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions. Journal of the American Heart Association. 2016;5(10):e003788. https://doi.org/10.1161/JAHA.116.003788
  13. Merli GJ, Hollander JE, Lefebvre P, Laliberté F, Raut MK, Germain G, Bookhart B, Pollack CV. Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin. Journal of Medical Economics. 2016;19(1):84-90. https://doi.org/10.3111/13696998.2015.1096274
  14. Kahler ZP, Beam DM, Kline JA. Cost of Treating Venous Thromboembolism With Heparin and Warfarin Versus Home Treatment With Rivaroxaban. Academic Emergency Medicine: Official Journal of the Society for Academic Emergency Medicine. 2015;22(7):796-802. https://doi.org/10.1111/acem.12713
  15. Deitelzweig S, Laliberté F, Crivera C, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting. Clinical Therapeutics. 2016;38(8):1803-1816.e3. https://doi.org/10.1016/j.clinthera.2016.07.002
  16. Kelliher S, Hall P, Kevane B, Dinu D, Ewins K, MacMahon P, Ní Áinle F, Breslin T. Implementation of an acute DVT ambulatory care pathway in a large urban centre: current challenges and future opportunities. Thrombosis Journal. 2019;17:14-14. https://doi.org/10.1186/s12959-019-0203-y
  17. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119-2126. https://doi.org/10.1111/jth.13140
  18. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis: JTH. 2005;3(4):692-694. https://doi.org/10.1111/j.1538-7836.2005.01204.x
  19. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal. 2013;11(1):21. https://doi.org/10.1186/1477-9560-11-21
  20. Einstein Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510. https://doi.org/10.1056/NEJMoa1007903
  21. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni, P. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine. 2017;376(13):1211-1222. https://doi.org/10.1056/NEJMoa1700518
  22. Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E, Turpie AGG. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. The Lancet Haematology. 2016;3(1):12-21. https://doi.org/10.1016/S2352-3026(15)00257-4
  23. Kreutz R, Mantovani LG, Haas S, Monje D, Schneider J, Bugge, J-P, Gebel M, Tamm M, Ageno W, Turpie AGG. XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America. Thrombosis Research. 2019;176:125-132. https://doi.org/10.1016/j.thromres.2019.02.010
  24. Schastlivtsev IV, Lobastov KV, Barinov VE, Vorontsova AV, Tsaplin SN, Barinova IV, Boyarintsev VV. The effectiveness and the safety of rivaroxaban in comparison with vitamin K antagonists during the long-term treatment of venous thrombosis. Flebologiya. Journal of Venous Disorders. 2016;10(1): 19-28. https://doi.org/10.17116/flebo201610119-28
  25. Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandowski B, Kovacs MJ. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003;349(13): 1227-1235. https://doi.org/10.1056/NEJMoa023153
  26. Lozano F, Trujillo-Santos J, Barrón M, Gallego P, Babalis D, Santos M, Falgá C, Monreal M. Riete Investigators, Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs. Journal of Vascular Surgery. 2014;59(5):1362-1367.e1. https://doi.org/10.1016/j.jvs.2013.11.091
  27. Trujillo-Santos J, Lozano F, Lorente MA, Adarraga D, Hirmerova J, Del Toro J, Mazzolai L, Barillari G, Barrón M, Monreal M; RIETE Investigators. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the lower limbs. The American Journal of Medicine. 2015;128(1): 90.e9-15. https://doi.org/10.1016/j.amjmed.2014.08.023